NovaGo Therapeutics is developing anti-Nogo-A antibodies aimed at a first regenerative treatment for acute spinal cord injuries. The biotech closed a Series B round of CHF 24 million (USD 30 million), co-led by Neurimmune and Pureos and complemented by non-dilutive funding, to fund a 120-patient proof-of-concept study.
- Announced on
- Round
- Series B
- Amount
- CHF 24 M
- Location
- Schlieren, canton of Zurich
- Sector
- Biotech & life sciences
Investors
- Neurimmune lead
- Pureos Bioventures lead
- Swiss Paraplegic Foundation
- Wings for Life
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic